Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination

J Neuroimmunol. 2016 Jan 15:290:49-53. doi: 10.1016/j.jneuroim.2015.11.006. Epub 2015 Nov 19.

Abstract

Rituximab, a monoclonal B-cell cytolytic antibody, has beneficial effects in patients with inflammatory demyelinating diseases. So far, little data exists on B-cell subset recovery after rituximab treatment in inflammatory demyelinating diseases of the central nervous system (CNS). To elucidate whether rituximab promotes qualitative changes in the IgG memory B-cell repertoire we performed a single cell analysis in three patients with CNS demyelination. We did not observe any qualitative changes but detected an increased clonal expansion in the IgG memory B-cell compartment after treatment, indicating that a single course of rituximab does not eliminate specific IgG memory B-cells.

Keywords: B-cells; Clonal expansion; Multiple sclerosis; Neuromyelitis optica; Rituximab.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology*
  • Demyelinating Autoimmune Diseases, CNS / drug therapy*
  • Demyelinating Autoimmune Diseases, CNS / immunology*
  • Female
  • Humans
  • Immunoglobulin G / immunology*
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology
  • Rituximab / pharmacology
  • Rituximab / therapeutic use*
  • Young Adult

Substances

  • Immunoglobulin G
  • Immunologic Factors
  • Rituximab